Accessibility Menu
Telix Pharmaceuticals logo

Telix Pharmaceuticals(OTC) TLPPF

Market Cap$3.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+917%
5 Year+119%
1 Year+13%
1 Month+12%
$11.65
+5.13%
+0.57Today
Telix Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 11.082026-08-31
Telix Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.54%USD 11.372026-08-24
1 month+12.34%USD 9.862026-07-30
3 month+23.13%USD 9.002026-06-02
Year to date+43.25%USD 7.742025-12-31
1 year+12.5%USD 9.852025-08-29
3 year+57.75%USD 7.032023-09-01
5 year+119.44%USD 5.052021-09-01
Since inception+916.66%USD 1.092019-07-25

Telix Pharmaceuticals Financials at a Glance

Market Cap

$3.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.50B

Net Income (TTM)

A$81.87M

EPS (TTM)

$0.09

P/E Ratio

112.28

Dividend

$0.00

Beta (Volatility)

0.42 (Low)

Price

$11.65

Volume

1,000

Open

$11.65

Previous Close

$11.65

Daily Range

$11.65 - $11.65

52-Week Range

$5.91 - $12.50

Estimated Earnings Date

Feb 19, 2027

TLPPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals. The company operates in three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions, with a strong emphasis on innovative cancer treatments.

Products and Services
  • TLX591: A lutetium-labeled radio antibody-drug conjugate for advanced prostate cancer
  • TLX250: An rADC targeting advanced metastatic kidney cancer
  • Illuccix and Gozellix: Radiopharmaceuticals for prostate cancer treatment
Growth Outlook
  • Recent quarterly revenue reached AUD 630.7 million, indicating strong market demand
  • Ongoing Phase 3 trials for TLX591 and TLX250 highlight significant development potential
  • Strategic collaborations with leading institutions enhance research capabilities and market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 2.1 billion reflects robust growth
  • Operating income margin improved to 1.58% in the latest quarter
  • Cash and cash equivalents stood at AUD 212.7 million, providing a solid financial foundation
Telix Pharmaceuticals Limited is positioned at the forefront of the biotechnology industry, focusing on precision medicine to address unmet medical needs in oncology. The company's innovative product pipeline, including TLX591 and TLX250, demonstrates its commitment to advancing cancer treatment through targeted therapies. Recent financial performance indicates a strong revenue trajectory, supported by ongoing clinical trials and strategic partnerships. With a solid cash position, Telix is well-equipped to continue its growth and development in the competitive biopharmaceutical landscape.
AI Generated • Aug 17, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,184

CEO

Christian P. Behrenbruch, PhD, EMBA

Website

www.telixpharma.com

Headquarters

North Melbourne, VIC 3051, AU

TLPPF Financials

Key Financial Metrics (TTM)

Gross Margin

52.16%

Operating Margin

-0.73%

Net Income Margin

3.60%

Return on Equity

7.11%

Return on Capital

2.08%

Return on Assets

2.40%

Earnings Yield

0.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

339.78M

Volume

1.00K

Avg. Volume

3.18K

Financials (TTM)

Gross Profit

A$1.36B

Operating Income

A$74.61M

EBITDA

A$132.08M

Operating Cash Flow

A$9.31M

Capital Expenditure

-A$97.55M

Free Cash Flow

-A$82.76M

Cash & ST Invst.

A$363.10M

Total Debt

A$835.81M

Telix Pharmaceuticals Performance Analysis

Telix Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31AUD 110,983,5751846.6%
20232023-12-31AUD 333,573,719200.6%
20242024-12-31AUD 516,602,59754.9%
20252025-12-31AUD 803,794,00055.6%
Telix Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31214.5%
Q22025-06-30-0.2%
Q42025-12-316.3%
Q22026-06-307.6%
Telix Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31AUD -0.238.5%
20232023-12-31AUD 0.01N/A
20242024-12-31AUD 0.10791.6%
20252025-12-31AUD -0.02N/A
Telix Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31230.3%
Q22025-06-30-109.4%
Q42025-12-31-110.7%
Q22026-06-30837.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$678.51M

+259.1%

Gross Profit

A$350.00M

+182.5%

Gross Margin

51.58%

N/A

Market Cap

$3.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.18M

N/A

Employees

1,184

N/A

Net Income

A$54.48M

+366.5%

EBITDA

A$16.97M

-57.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$363.10M

+205.5%

Total Debt

A$835.81M

+3674.6%

Accounts Receivable

A$245.60M

+152.5%

Inventory

A$56.26M

+82.6%

Long Term Debt

A$813.58M

+4330.0%

Short Term Debt

A$22.23M

+488.0%

Return on Assets

2.40%

N/A

Return on Invested Capital

-0.59%

N/A

Free Cash Flow

A$5.79M

-70.9%

Operating Cash Flow

A$32.74M

-2.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNPHYSanten Pharmaceutical Co., Ltd.
$11.95+6.41%
CAMRFCamurus AB
$61.75+0.00%
ANSLFAnsell Limited
$21.64+0.00%
BVNRYBavarian Nordic A/S
$11.34-0.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About TLPPF

What is the current price of Telix Pharmaceuticals?

Telix Pharmaceuticals is trading at $11.65 per share.

What is the 52-week range for Telix Pharmaceuticals?

Over the past 52 weeks, Telix Pharmaceuticals has traded between $5.91 and $12.50.

How much debt does Telix Pharmaceuticals have?

As of the most recent reporting period, Telix Pharmaceuticals reported total debt of A$467.11M.

How much cash does Telix Pharmaceuticals have on hand?

Telix Pharmaceuticals reported A$141.87M in cash and cash equivalents in its most recent financial results.

What is Telix Pharmaceuticals’s dividend yield?

Telix Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services